Page last updated: 2024-12-09

2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide is a synthetic molecule with the chemical formula C₁₁H₇F₃N₂O₃S. It's a complex compound that combines various functional groups, including:

* **Thiazolidine ring:** A five-membered ring containing sulfur, nitrogen, and carbon atoms.
* **Dioxo group:** Two carbonyl groups (C=O) attached to the thiazolidine ring.
* **Acetamide group:** An amide group (NHCOCH₃) attached to the thiazolidine ring.
* **Trifluorophenyl group:** A phenyl ring with three fluorine atoms attached to it.

**Importance for Research:**

This molecule's unique structure and combination of functional groups make it relevant for several areas of research, including:

* **Pharmacology and Drug Discovery:**
* **Antimicrobial activity:** Thiazolidine derivatives often exhibit antimicrobial activity against bacteria, fungi, and viruses. This compound could be a lead candidate for developing novel antibiotics or antifungal agents.
* **Anti-inflammatory activity:** Certain thiazolidine derivatives have demonstrated anti-inflammatory properties. The trifluorophenyl group might contribute to this activity by interacting with inflammatory pathways in the body.
* **Antioxidant activity:** The sulfur atom in the thiazolidine ring can act as a radical scavenger, potentially offering antioxidant properties.
* **Materials Science:**
* **Polymer chemistry:** Thiazolidine derivatives can act as monomers, building blocks for polymers with unique properties. The trifluorophenyl group could enhance the thermal and chemical stability of the polymer.
* **Analytical Chemistry:**
* **Chromatographic analysis:** The molecule's structure and properties might make it a valuable analytical standard or reagent for chromatography techniques.

**Specific Research Areas:**

There is limited publicly available information about this specific compound. However, the general structure suggests potential research applications:

* **Synthesis and Characterization:** Researchers might be interested in developing efficient synthesis methods for this compound and studying its physicochemical properties like melting point, solubility, and spectral characteristics.
* **Biological Activity Studies:** Biological assays would be necessary to determine the compound's potential antimicrobial, anti-inflammatory, or antioxidant activities.
* **Structure-Activity Relationship (SAR):** Modifying the structure of this compound, for example, by changing the substituents on the phenyl ring or the thiazolidine ring, could help identify more potent and selective analogues for specific biological targets.

**Overall:**

2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide represents a starting point for further research in various fields, particularly in drug discovery, materials science, and analytical chemistry. Further research and studies are needed to fully explore its potential applications and unlock its therapeutic or technological benefits.

Cross-References

ID SourceID
PubMed CID648553
CHEMBL ID1528050
CHEBI ID121058

Synonyms (14)

Synonym
smr000014273
2-(dioxo-thiazolidin-3-yl)-n-(2,3,4-trifluoro-phenyl)-acetamide
BAS 07213796
MLS000075181
CHEBI:121058
AKOS000400151
2-(2,4-dioxo-1,3-thiazolidin-3-yl)-n-(2,3,4-trifluorophenyl)acetamide
HMS2353F13
STL380763
CHEMBL1528050
2-(2,4-dioxo-3-thiazolidinyl)-n-(2,3,4-trifluorophenyl)acetamide
Q27209296
sr-01000320338
SR-01000320338-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.11890.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency39.81070.631035.7641100.0000AID504339
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID540317
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency23.77810.168316.404067.0158AID720504
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]